Help Relieve Their Tension Headaches

With an FDA-approved low dose of acetaminophen
(300 mg) in a butalbital combination prescription
product1

  • With No Caffeine1
  • With No Aspirin1
With Proven Active Ingredients1

EACH TABLET CONTAINS:

Butalbital, USP 50 mg

Warning: may be
habit-forming

Acetaminophen, USP 300 mg

Consider BUPAP for Patients Who Don't Need
Additional Caffeine

Caffeine Prevalence in the United States
  • Almost 2/3 of the caffeine intake of US adults comes from coffee 2
  • Coffee is the most commonly consumed beverage after water3
  • 61% of population aged 18 and older are coffee drinkers3

Demand Brand-Name BUPAP for Co-pay Savings

For Doctors For Your Patients
  • Indicate no substitution to avoid a switch at the pharmacy
  • Check their prescription to make sure it’s written for brand-name BUPAP
  • Indicate "DAW," "Brand Only," or
    "Brand Medically Necessary" depending on the
    state you live in
  • Remind them to check their bag at the pharmacy to make sure they didn’t receive a generic alternative
  • The Co-pay Card only works when the brand-name drug is dispensed
  • Encourage them to check their receipt for prescription savings with the Co-pay Card
FOR DOCTORS

Indicate no substitution to avoid a switch at the pharmacy

Indicate "DAW," "Brand Only," or
"Brand Medically Necessary" depending on the
state you live in

The Co-pay Card only works when the brand-name drug is dispensed

FOR YOUR PATIENTS

Check their prescription to make sure it’s written for brand-name BUPAP

Remind them to check their bag at the pharmacy to make sure they didn’t receive a generic alternative

Encourage them to check their receipt for prescription savings with the Co-pay Card

*ELIGIBILITY AND RESTRICTIONS: This savings card allows commercially insured patients to have a no more than $25 out-of-pocket expense for their Bupap®. The offer is limited as directed by the physician and in accordance with package insert instructions. Offer good only in the USA. This offer is not valid if your prescription is paid/partially paid by Medicaid, Medicare, Federal or State government programs. By using this offer, you agree that you will not submit a claim for the prescription to a government payer such as Medicare or Medicaid. Patients are responsible for reporting receipt of this offer to any health insurer, health plan, or third-party payer as may be required. The use of this offer is subject to applicable state and federal law. The offer is not available to uninsured patients. ECR Pharmaceuticals reserves the right to rescind, revoke or amend this offer without notice. Void where prohibited by law.


Click here to
download the BUPAP Co-Pay Card savings offer*

*ELIGIBILITY AND RESTRICTIONS: This savings card allows commercially insured patients to have a no more than $25 out-of-pocket expense for their Bupap®. The offer is limited as directed by the physician and in accordance with package insert instructions. Offer good only in the USA. This offer is not valid if your prescription is paid/partially paid by Medicaid, Medicare, Federal or State government programs. By using this offer, you agree that you will not submit a claim for the prescription to a government payer such as Medicare or Medicaid. Patients are responsible for reporting receipt of this offer to any health insurer, health plan, or third-party payer as may be required. The use of this offer is subject to applicable state and federal law. The offer is not available to uninsured patients. ECR Pharmaceuticals reserves the right to rescind, revoke or amend this offer without notice. Void where prohibited by law.



INDICATION

BUPAP® (butalbital and acetaminophen tablets), 50mg/300mg are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.

IMPORTANT SAFETY INFORMATION

Hepatotoxicity: Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen containing product.

  • BUPAP (butalbital and acetaminophen tablets), 50mg/300mg is contraindicated under the following conditions:
    • Hypersensitivity or intolerance to any component of this product.
    • Patients with porphyria.
  • Butalbital is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.
  • The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.
  • Acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Patients should be informed about the signs of severe skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.
  • There have been post-marketing reports of hypersensitivity and anaphylaxis associated with use of acetaminophen. Clinical signs include swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting. There were infrequent reports of life-threatening anaphylaxis requiring emergency medical attention. Instruct patients to discontinue BUPAP immediately and seek medical care if they experience these symptoms. Do not prescribe BUPAP for patients with acetaminophen allergy.
  • BUPAP (butalbital and acetaminophen tablets) 50mg/300mg should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, or acute abdominal conditions.
  • The most frequently reported adverse reactions are drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, abdominal pain, and intoxicated feeling.

» Click here for full Prescribing Information.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INDICATION

BUPAP® (butalbital and acetaminophen tablets), 50mg/300mg are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.

IMPORTANT SAFETY INFORMATION

Hepatotoxicity: Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen containing product.

  • BUPAP (butalbital and acetaminophen tablets), 50mg/300mg is contraindicated under the following conditions:
    • Hypersensitivity or intolerance to any component of this product.
    • Patients with porphyria.
  • Butalbital is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.
  • The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.
  • Acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Patients should be informed about the signs of severe skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.
  • There have been post-marketing reports of hypersensitivity and anaphylaxis associated with use of acetaminophen. Clinical signs include swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting. There were infrequent reports of life-threatening anaphylaxis requiring emergency medical attention. Instruct patients to discontinue BUPAP immediately and seek medical care if they experience these symptoms. Do not prescribe BUPAP for patients with acetaminophen allergy.
  • BUPAP (butalbital and acetaminophen tablets) 50mg/300mg should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, or acute abdominal conditions.
  • The most frequently reported adverse reactions are drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, abdominal pain, and intoxicated feeling.

» Click here for full Prescribing Information.